Tissue Genesis Email Format
BiotechnologyUnited States11-50 Employees
Tissue Genesis is a United States-based biotechnology research firm focused on technologies supporting regenerative medicine and cell therapy. In 2018, it introduced the Icellator X, a system for isolating stem cells from adipose tissue. The company underwent a leadership transition in December 2021 with the retirement of its president and chief executive officer, Krucky. In 2020, Tissue Genesis transferred substantially all of its assets to Orgenesis, reflecting a corporate restructuring. The organization operates within the biotechnology research field, aiming to support researchers and organizations pursuing regenerative medicine and cell therapy, with emphasis on stem cell technologies.